Received: 21 December 2007,

(www.interscience.wiley.com) DOI:10.1002/cmmi.233

Revised: 13 March 2008, Accepted: 14 March 2008,

-- -----

Published online in Wiley InterScience: 00 Month 2008

In vivo MRI assessment of a novel Gd^{III}-based contrast agent designed for high magnetic field applications

Paulo Loureiro de Sousa^{a†}, João Bruno Livramento^b, Lothar Helm^b, André E. Merbach^b, William Même^c, Bich-Thuy Doan^{a,d}, Jean-Claude Beloeil^a, Maria I. M. Prata^e, Ana C. Santos^e, Carlos F. G. C. Geraldes^f and Éva Tóth^{a,b*}

Gd₃L is a trinuclear Gd³⁺ complex of intermediate size, designed for contrast agent applications in high field magnetic resonance imaging (H₁₂L is based on a trimethylbenzene core bearing three methylene-diethylenetriamine-*N*,*N*,*N*",*N*"-tetraacetate moieties). Thanks to its appropriate size, the presence of two inner sphere water molecules and a fast water exchange, Gd₃L has remarkable proton relaxivities at high magnetic field ($r_1 = 10.2 \text{ vs } 3.0 \text{ mm}^{-1} \text{ s}^{-1}$ for GdDOTA at 9.4 T, 37°C, in H₂O). Here we report an *in vivo* MRI feasibility study, complemented with dynamic γ scintigraphic imaging and biodistribution experiments using the ¹⁵³Sm-enriched analog. MRI experiments were performed at 9.4 T in mice with Gd₃L and the commercial contrast agent gadolinium(III)-1,4,7,10-tetraazetate (GdDOTA). Gd₃L was well tolerated by the animals at the dose of 8 µmol Gd kg⁻¹ body weight. Dynamic contrast enhanced (DCE) images showed considerably higher signal enhancement in the kidney medulla and cortex after Gd₃L injection than after GdDOTA injection at an identical dose. The relaxation rates, ΔR_1 , were calculated from the IR TrueFISP data. During the excretory phase, the ΔR_1 for various tissues was similar for Gd₃L and GdDOTA, when the latter was injected at a three-fold higher dose (24 vs 8 µmol Gd kg⁻¹ body weight). These results point to an approximately three times higher *in vivo* relaxivity (per

* Correspondence to: Éva Tóth, Centre de Biophysique Moléculaire, CNRS, Rue Charles-Sadron - 45071 Orléans cedex 2, France. E-mail: eva.jakabtoth@cnrs-orleans.fr

† Present address: NMR Laboratory, AIM and CEA, Institut de Myologie, La Pitié-Salpêtrière University Hospital, Paris, France.

a P. L. de Sousa, B.-T. Doan, J.-C. Beloeil, É. Tóth Centre de Biophysique Moléculaire, CNRS, rue Charles Sadron, 45071 Orléans, France

b J. B. Livramento, L. Helm, A. E. Merbach, É. Tóth Laboratoire de Chimie Inorganique et Bioinorganique, Ecole Polytechnique Fédérale de Lausanne, EPFL-BCH; CH-1015 Lausanne, Switzerland

c W. Même UPRES EA 2633, Laboratoire de Neurobiologie, Université d'Orléans, Orléans, France

d B.-T. Doan ICSN, CNRS, avenue de la Terrasse, 91198 Gif sur Yvette, cedex, France

e M. I. M. Prata, A. C. Santos

Instituto de Biofísica e Biomatemática, Faculdade de Medicina, Universidade de Coimbra, Portugal

f C. F. G. C. Geraldes

Departamento de Bioquímica, Centro de RMN e Centro de Neurociências e Biologia Celular, Faculdade de Ciências e Tecnologia, Universidade de Coimbra, Coimbra, Portugal

Contract/grant sponsor: Centre National pour la Recherche Scientifique (France). Contract/grant sponsor: Swiss National Science Foundation. Contract/grant sponsor: Swiss State Secretariat for Education and Research. Contract/grant sponsor: Foundation of Science and Technology, Portugal; contract/grant number: POCTI/QUI/47005/2002. Contract/grant sponsor: FEDER. Contract/grant sponsor: EC COST Action D38. Contract/grant sponsor: EMIL programme; contract/grant number: LSCH-2004-503569. Contract/grant sponsor: Le Studium.

Abbreviations used: bpm, beats per minute; BW, body weight; CA, contrast agent; C(t), gadolinium concentration time course in tissue or blood; DCE, dynamic contrast enhanced; FLASH, fast low angle shot, fast gradient echo MRI method; FOV, field of view; CGd, gadolinium concentration; GdDOTA, gadoterate meglumine, type of MR contrast agent; HSA, human serum albumin; IR, inversion recovery; i.v., intravenous; PK, pharmacokinetic; RARE, rapid acquisition and relaxation enhancement, fast spin echo MRI method; ROI, region of interest; T1, spin-lattice relaxation time in MR; TE, echo time; TI, inversion time; TR, repetition time; IR TrueFISP, inversion recovery TrueFISP imaging.

Gd) for Gd₃L relative to GdDOTA, thus the ratio of the relaxivities of the two compounds determined *in vitro* is retained under *in vivo* conditions. They also indicate that the two inner sphere water molecules per Gd in Gd₃L are not substantially replaced by endogenous anions or other donor groups under physiological conditions. Gd₃L has a pharmacokinetics typical of small, hydrophilic complexes, involving fast renal clearance and no retention in the blood pool. The dynamic γ scintigraphic studies and the biodistribution experiments performed in Wistar rats with ¹⁵³Sm-enriched *Sm₃L are also indicative of a fast elimination via the kidneys. Copyright © 2008 John Wiley & Sons, Ltd.

Keywords: magnetic resonance imaging; high magnetic field; contrast agents; gadolinium; *in vivo*; pharmacokinetics; biodistribution; γ imaging

1. INTRODUCTION

In magnetic resonance imaging, higher field strength is translated to a better sensitivity and greater spatial or temporal resolution, which explains the current tendency to increase the magnetic field in both clinical and experimental settings. While today 1.5 T remains the predominant field strength in the clinics, the 3 T magnet continues to gain market share. In experimental animal studies, magnetic fields \geq 7.0 T are commonly applied (1). The signal-to-noise ratio correlates in approximately linear fashion with field strength, thus by increasing the field, the time needed to acquire satisfactory images can be substantially reduced. Alternatively, during the same acquisition time, images at higher resolution can be obtained. Functional MRI and MR spectroscopy benefit particularly from high magnetic fields.

Stable poly(amino carboxylate) complexes of Gd³⁺ are widely used to enhance image contrast in MRI (2-4). In the last two decades, much effort has been devoted to the improvement of the efficacy of these contrast agents, by modifying the microscopic parameters of the Gd³⁺ chelates via an appropriate ligand design. For instance, the optimization of the rotational motion by applying slowly tumbling macromolecular complexes led to a considerable relaxivity increase in the intermediate field range, as compared with the commercial, small molecular weight agents GdDTPA or GdDOTA. Typically, these macromolecular chelates have a high proton relaxivity peak centred between 20 and 60 MHz. Above this frequency, their longitudinal relaxivity strongly vanishes with increasing field, and at high fields very slow rotation is not beneficial any more for relaxivity. Indeed, the Solomon-Bloembergen-Morgan theory of paramagnetic relaxation (5) predicts that at frequencies above $\sim 200 \, \text{MHz}$ the relaxivity increases with the inverse of the rotational correlation




Figure 1. Schematic representation of Gd₃L.

time $\tau_{\rm R}$, in contrast to that at lower frequencies, where it is proportional to $\tau_{\rm B}$. Consequently, at very high fields intermediate size molecules are favorable over very large ones. Recently we have reported a self-assembled metallostar system with remarkably high in vitro relaxivities at 200 and 400 MHz (6,7). The high efficacy of the metallostar has also been confirmed under in vivo conditions in mice in a comparative MRI study (8). The signal enhancement in the inversion recovery fast low angle shot (IR FLASH) images after the injection of the metallostar at 0.05 mmol Gd kg⁻¹ body weight (BW) was considerably higher than after GdDOTA injection (at 0.1 mmol Gd kg^{-1} BW), despite the higher dose of the latter. The metallostar injection resulted in a greater drop in the spin-lattice relaxation time (T_1) , as calculated from the inversion recovery TrueFISP imaging (IR TrueFISP) data for various tissues, than the GdDOTA injection. This study also indicated similar pharmacokinetics for the metallostar and for GdDOTA, involving fast renal clearance, a leakage to the extracellular space in the muscle tissue and no leakage to the brain.

One drawback of the metallostar is the limited stability of the Fe²⁺-tris(bipyridine) core, leading to a slow decomposition in biological conditions which might raise toxicity concerns (7). In order to overcome this problem, a novel chelate, H₁₂L, was designed involving covalent linking of three DTTA units to a central xylyl core (DTTA⁴⁻ = diethylene-triamine-tetraacetate). The ligand H₁₂L forms a trinuclear Gd³⁺ complex, Gd₃L, (Fig. 1) which has the appropriate, intermediate size to attain high relaxivities at 4.7-9.4 T. The synthesis of the ligand and the physico-chemical characterization of the Gd³⁺ complex have been reported elsewhere (9). The in vitro measurements showed that the Gd₃L complex indeed has considerably higher r_1 values at high field as compared with the commercial agents (Table 1). At 400 MHz and 37°C, its relaxivity is three times superior to that of GdDOTA (10.2 vs $3.0 \text{ mm}^{-1} \text{ s}^{-1}$). In addition to the appropriate size of the complex, the presence of two inner sphere water molecules and their efficient exchange rate are also important factors to contribute to this remarkable relaxivity (9).

Table 1. High field relaxivities	of selected Gd ³	+ complexes
measured in water (pH 7.4)		

	200 MHz	200 MHz (4.7 T)		400 MHz (9.4 T)	
<i>r</i> ₁ (mm ⁻¹ s ⁻¹)	25°C	37°C	25°C	37°C	
Gd ₃ L Metallostar ^a GdDOTA ^a GdDTPA	17.0 16.4 4.0 4.2	14.1 15.8 3.0 3.2	10.7 9.3 3.9 4.1	10.2 8.5 3.0 3.1	
^a Livramento <i>et al</i> . (8).					

79

Here we report an *in vivo* MRI feasibility study at 9.4 T using Gd₃L as a potential MRI contrast agent dedicated to high magnetic fields. The pharmacokinetics and *in vivo* relaxivity were assessed in mice and compared with those of a typical commercial, small molecular weight contrast agent, GdDOTA. The MRI results have been complemented with dynamic scintigraphic and biodistribution studies in Wistar rats at short (10–15 min) and long (24 h) periods of time by using the ¹⁵³Sm analog compound, ¹⁵³Sm₃L.

2. RESULTS AND DISCUSSION

2.1. Magnetic resonance imaging

Comparative MRI studies have been performed at 9.4 T in mice with Gd₃L and GdDOTA. Gd₃L was well tolerated by the animals at the dose of 8 μ mol Gd kg⁻¹ BW. No gross side effects were observed during the injection, immediately or several days after the experiment. During the experiment, the respiration of the animal was continuously monitored. In the first minute post-injection, a drop in the respiration frequency was detected. The values returned to the pre-injection level after a few minutes. Overall, Gd₃L seemed to be harmless to the animals; nevertheless, a more detailed study would be required to further assess its toxicology.

The toxicity of novel Gd^{3+} complexes to be tested in *in vivo* experiments is an important concern. The Gd^{3+} chelate has to be sufficiently stable to avoid any Gd^{3+} release before total excretion

of the contrast agent from the body. This requires sufficient thermodynamic stability and kinetic inertness of the complex (10). Thermodynamic stability was assessed for various GdDTTAtype complexes and showed a limited decrease as compared with GdDTPA. The stability constants determined for the Gd^{3+} complexes formed with DTTA-derivative chelators were $\log K_{GdL} = 17-19$, with corresponding pGd values of ~15-16 ([L]_{total} = 10 µм; [Gd]_{total} = 1 µм; pH 7.4) (7,11). These pGd values are very similar to that of GdDTPA-BMA (pGd = 15.8), one of the clinically approved contrast agents (12). Nevertheless, we are aware that Gd₃L is just a model system and cannot be proposed for in vivo human applications. Recently, the lack of high kinetic inertness of certain Gd³⁺ complexes, in particular GdDTPA-BMA, has been recognized to be associated with the potentially lethal nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD). We have to note, however, that only patients with severe renal failure develop NSF; those who present a very slow excretion of the agent from the body. On the other hand, high-field imaging is primarily used in small animal studies and not for human applications. In small animals the excretion is much more rapid, and therefore the kinetic inertness of the complex is less critical.

2.2. DCE experiments

Figure 2 shows a representative series of dynamic contrast enhanced (DCE) images after Gd_3L and GdDOTA injections at the same dose of 8 μ mol Gd kg⁻¹ BW. In the pre-injection image,




Figure 2. Representative series of dynamic contrast enhanced images after Gd_3L injection at a dose of 8 μ mol Gd kg⁻¹ BW. In the pre-injection images (first four images), kidney structures (cortex, inner and outer medulla) and adjacent tissues were dark due to the particular inversion delay chosen. A marked change of signal intensity was observed in the vascular system (artery aorta and vein cava) just after bolus injection, followed by a signal enhancement in the renal cortex and later in the medulla. A slight enhancement in the muscle and liver was also observed; B = 9.4 T.




Figure 3. Dynamic contrast enhanced images after GdDOTA and Gd_3L injections at the dose of 8 μ mol Gd kg⁻¹ BW each. For both agents, marked changes of signal intensity were observed in the vascular system, renal cortex and medulla. At 10 min post-injection the signal enhancement observed after Gd₃L injection is considerably higher as compared with the GdDOTA injection, despite the identical dose of the two agents used; B = 9.4 T.

12 s post-inject.

10 min. post-inject.

kidney structures (cortex, inner and outer medulla) and adjacent tissues were dark due to the particular inversion delay chosen.

For both agents, marked changes of signal intensity were observed immediately after bolus injection in the vascular system (artery aorta and vena cava), followed by a signal enhancement in the renal cortex and later in the medulla (Fig. 3). A slight enhancement in the muscle and liver was also observed for both contrast agents (CAs). At 10 min post-injection, during the renal excretory phase, the signal enhancement observed after Gd₃L injection was considerably higher as compared with the GdDOTA injection, despite the identical dose of the two agents used. This finding is in accordance with the remarkably higher relaxivity of Gd_3L determined *in vitro*.

2.3. T₁ experiments

Pre-inject.

The time course of the relaxation rates ($\Delta R_1 = R_1 - R_{10} = 1/T_1 - 1/T_{10}$), calculated from the IR TrueFISP data, is shown in Fig. 4. The increase in the relaxation rate is supposed to be directly proportional to the concentration of the contrast agent delivered to the tissue, if saturation effects are absent. If *in vitro* CA relaxivities (Table 1) and ΔR_1 curves (Fig. 4) are used to estimate the local concentration in the kidney tissues and blood, the Gd concentration calculated is ~3 times higher for GdDOTA. This result is consistent with the experimental setup (mice have received a three-fold dose of GdDOTA).

The pharmacokinetics was found to be similar for Gd_3L and GdDOTA. Both CAs are primarily eliminated by the kidneys from the blood stream. These finding is in full accordance with previous reports on the pharmacokinetics of the GdDOTA (13–15) or other small molecular weight Gd-based contrast agents (14).

For both CAs, the vascular response was characterized by a sharp maximum ~ 10 s after the bolus injection followed by a rapid elimination from the blood. The cortex and medulla




Figure 4. Relaxation rates, ΔR_1 , calculated from the IR TrueFISP data after GdDOTA (top) and injection Gd₃L (bottom) for three different regions of interest: kidney cortex, kidney medulla and the vascular system. During the excretory phase (time > 4 min), ΔR_1 for renal tissues was similar for Gd₃L and GdDOTA when the latter was injected at a dose three times higher (24 µmol Gd kg⁻¹ BW). The time courses represent mean values of n = 6 animals. Symbols: (solid squares) cortex; (solid circles) medulla; (solid triangles) vascular system (cava); B = 9.4 T.

showed a similar clearance pattern, with a slower rate for medulla. As the elimination rate depends on the dose administered (15), the elimination curves observed for GdDOTA are slightly different from those described in Livramento *et al.* (8) as a consequence of the lower dose used here. For both CAs, the elimination curve approached a steady-state \sim 3 min after injection (a slowly descending segment, corresponding to the predominant excretory function).

For both CAs, the IR-TrueFISP experiment was not sensitive enough to detect T_1 changes in the muscles and liver (data not shown), probably due to the weak dose used and/or the very short T_2 found in these tissues.

It has been shown previously that the *in vitro* and *in vivo* relaxivities of Gd-based contrast agents can be significantly different, the latter being affected by the tissue structure and physiology (16,17). It has been demonstrated that GdDTPA has considerably lower relaxivities in the rat kidney cortex or medulla than measured in saline solution or in other tissues, which is related to the compartmentalization of the contrast agent in the kidney (18,19). Evidently, the quantitative determination of the *in vivo* relaxivity of a contrast agent requires knowledge of its local concentration. In some cases, this concentration has been

obtained by independent measurements. These studies, however, are not without difficulties, since they often induce significant perturbations to the tissues by studying intact excised tissues (20), making measurements post-mortem (18) or ensuring a constant infusion of the contrast agent in order to establish a steady state concentration (19). In the absence of such experiments, only an estimation of the relative *in vivo* relaxivity can be performed if we assume similar pharmacokinetics for GdDOTA and Gd₃L. In this case, the relative *in vivo* relaxivity of Gd₃L as compared with that of GdDOTA can be obtained by:

$$\frac{(r_1)_{\text{Gd}_3\text{L}}}{(r_1)_{\text{Gd}_{\text{DOTA}}}} = \frac{(\text{dose})_{\text{Gd}_{\text{DOTA}}}}{(\text{dose})_{\text{Gd}_3\text{L}}} \cdot \frac{(\Delta R_1)_{\text{Gd}_3\text{L}}}{(\Delta R_1)_{\text{Gd}_{\text{DOTA}}}}.$$
 (1)

For the sake of simplicity, if CA relaxivities are compared for the period of the excretory phase (a slowly descending segment, starting ~3 min post-injection, corresponding to the predominant excretory function), ΔR_1 for various tissues was similar for Gd₃L and GdDOTA, when the latter was injected at a dose three times higher (24 µmol Gd kg⁻¹ BW). Table 2 summarizes the variation of ΔR_1 across different regions of the kidney after Gd₃L and GdDOTA injection, during the excretory phase. No significant (p < 0.01) differences were found between the ΔR_1 values measured for the two different contrast agents, despite the different doses applied. Using the average ΔR_1 values given in Table 2 and taking into account the 3-fold higher dose of GdDOTA, we find that the *in vivo* r_1 for Gd₃L is approximately three times higher than for GdDOTA.

The renal clearance, based on the observation of the ΔR_1 values in the three different regions of interest (kidney cortex, kidney medulla and the vascular system), was similar to that previously reported for the metallostar compound (8) and for other small-molecular-weight Gd-based contrast agents (13,14). As the high ΔR_1 values of the kidney medulla show, Gd₃L is predominantly eliminated from the blood stream by the kidneys, analogously to GdDOTA or to other small chelates. Furthermore, as expected on the basis of its relatively small size, Gd₃L does not function as a blood pool agent.

Clearly, we do not have any evidence on the identical biodistribution of GdDOTA and Gd_3L . As explained above, the quantitative assessment of the *in vivo* contrast agent concentration can be only achieved via very invasive methods, which were beyond the scope of this study. In order to proceed in the most cautious way, the comparison of the relaxivity of the two compounds was done in the excretory phase where the experimentally measured relaxation rates attain a very slowly descending segment. In this quasi-stationary phase, different pharmacokinetic behavior has less influence on the comparison. We believe that the fact that the relaxivity ratio calculated is close to what is found *in vitro* is probably not a coincidence. Also, the

Table 2. Average ΔR_1 values ($n = 6$, mean \pm SD) in various
kidney regions during the excretory phase; $B = 9.4 \text{ T}$

Region	$\Delta R_1 (s^{-1})$ Gd ₃ L; 8 mmol kg ⁻¹ BW	$\Delta R_1 (s^{-1})$ GdDOTA; 24 mmol kg ⁻¹ BW
Kidney cortex Kidney medulla Aorta/cava	$\begin{array}{c} 0.43 \pm 0.07 \ s^{-1} \\ 0.71 \pm 0.19 \ s^{-1} \\ 0.19 \pm 0.05 \ s^{-1} \end{array}$	$\begin{array}{c} 0.49 \pm 0.07 \ s^{-1} \\ 0.64 \pm 0.20 \ s^{-1} \\ 0.25 \pm 0.05 \ s^{-1} \end{array}$

time-dependent relaxation rates measured in the blood (Fig. 4, blue curves) seem to indicate that the rate of elimination of the agent from the blood is very similar for the two compounds.

Furthermore, the high relaxation efficiency of Gd_3L under *in vivo* conditions suggests that the two inner sphere water molecules are not (or not substantially) replaced by endogenous anions or other potential donors from proteins, etc., in the biological medium. The same observation was made in the animal imaging experiments previously performed with the metallostar compound, containing an identical DTTA chelator to complex Gd^{3+} . This finding is very important and favors the DTTA chelates in comparison to the macrocyclic bishydrated DO3A-type Gd^{3+} complexes, which tend to form ternary complexes with a variety of endogenous carboxylate donors (21).

2.4. Biodistribution and dynamic scintigraphic studies

In order to gain further insight into the *in vivo* behaviour of the trinuclear Gd₃L, we performed biodistribution and dynamic γ scintigraphic studies in Wistar rats using the Sm³⁺ analog complex where the gadolinium was replaced by a mixture of radioactive (¹⁵³Sm) and non-radioactive samarium (22,23).

The scintigraphic image obtained 200 s after tracer injection of Sm^*_{3L} is shown in Fig. 5. As this figure shows, and in full accordance with the MRI findings, the main activity is located in the kidneys and the bladder, which represent the typical excretion pathway for such a small and hydrophilic complex. A rapid clearance from all other organs is also observed. The time–activity curves, obtained from the dynamic acquisition experiments, are shown in Fig. 6. The curves were smoothed and normalized in relation to the maximum activity obtained. The clearance of the compound via the kidneys was confirmed again. The liver–spleen curve was similar to the thorax curve, corresponding only to blood activity.

The characteristics of the renal clearance and washout of $Sm_{3}^{*}L$ were further investigated by biodistribution studies in Wistar rats. The results obtained at 15 min and 24 h post-injection




Figure 5. Scintigraphic dynamic image obtained 200 s after intravenous injection of $^{153}\rm{Sm}_{3}L$ in a Wistar rat. This figure is available in colour online at www.interscience.wiley.com/journal/cmmi




Figure 6. Time-activity curves obtained from dynamic scintigraphic images for the various regions of interest. The y-axis represents the normalized activity. This figure is available in colour online at www.interscience.wiley.com/journal/cmmi




Figure 7. Biodistribution, stated as percentage of injected dose per gram of organ (%ID/g \pm SD), of ¹⁵³Sm₃L in Wistar rats: (a) 15 min and (b) 1 h after intravenous injection. Results are the mean values of four animals.

are summarized in Fig. 7. At 15 min, the activity is overwhelmingly localized in the urine (% ID g⁻¹ in urine = 10.0 ± 5.12), which is in agreement with what was observed in the scintigraphic experiments. As expected, at 24 h after injection the activity dramatically decreased in all organs with the exception of the liver. The reason for such activity in the liver is still not clear. In the first instance it could probably be attributed to some later metal decomplexation; however if that was the case the activity value in the spleen and femur should also corroborate such an increase, which is not all observed.

3. CONCLUSIONS

Given its appropriate size and the corresponding rotational dynamics, Gd_3L has remarkable proton relaxivities at high magnetic field and is a prime candidate for CA applications in small animal MR imaging at high fields. MRI studies performed at 9.4 T in mice indicated that the *in vivo* r_1 relaxivity of Gd_3L is approximately three times higher than that of GdDOTA. The pharmacokinetics is similar for Gd_3L and GdDOTA, both following fast renal clearance in mice. Dynamic scintigraphic studies performed in rats using Sm_3L with ¹⁵³Sm enrichment are in accordance with this elimination pathway. The biodistribution

results obtained at 15 min and 24 h post-injection gave further support to the scintigraphic and MRI results.

4. **EXPERIMENTAL**

153-Samarium chloride (153 SmCl₃) was produced at the ITN (Instituto Tecnológico e Nuclear), Lisbon, with a specific activity >5 GBq mg⁻¹. For this purpose a 153 Sm₂O₃ was prepared from a 98% samarium-152 enriched samarium oxide target, sealed into a quartz vial and welded into an aluminum can, by neutron irradiation using a thermal flux of 2.3×10^{13} n cm⁻² s⁻¹. Following irradiation, the sample was opened, dissolved in HCl (1 m) and the final 153-samarium chloride (153 SmCl₃) was brought to a stock concentration of 1.9 mm.

4.1. Sample preparation

A GdCl₃ solution was prepared from Gd₂O₃ of 99.9% purity (Fluka) by dissolution in excess HCl, which was evaporated off. The concentration of the metal ion was determined by complexometric titration with standardized Na_2H_2EDTA solution. The synthesis of the ligand $H_{12}L$ has been described previously (9). Gd₃L was prepared by adding solid ligand to a solution of

 $GdCl_3$ in 1:3 ligand to metal molar ratio. The pH, measured with a calibrated combined glass electrode, was adjusted to 7.1 by addition of known amounts of NaOH (0.1 m). The absence of free metal was checked by the xylenol orange test.

Sm₃L was prepared by adding a ligand solution (pH 6.8) to a solution of SmCl₃ (Sigma-Aldrich), where the concentration of the metal ion was determined by complexometric titration with standardized Na₂H₂EDTA solution. A solution of ¹⁵³SmCl₃ (~74 MBq) was then added to the previous solution to reach 3:1 overall metal:ligand ratio.

4.2. Animals

MRI studies were performed in agreement with the French guidelines for animal care and in compliance with procedures approved by the appropriate institutional review committees. *In vivo* experiments were performed in male FVB/N mice (8–10 weeks, 24–26 g, obtained from Janvier Laboratories, Le Genest-St-Isle, France). All animals were kept in an animal housing facility, and given *ad libitum* access to food and water.

4.3. CA injection

Gd₃L (10 mm) was injected in mice as a bolus via a tail vein catheter at a dose of 8 μ mol Gd kg⁻¹ body weight. For comparison, the experiments were repeated with injection of the small molecular weight contrast agent gadolinium(III)-1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetate ([Gd(DOTA) (H2O)]⁻ = GdDOTA) (Dotarem, Guerbet, France).

The *in vitro* r_1 relaxivity at 9.4 T was approximately 3 times larger for Gd₃L than for GdDOTA (9). Thus, in the experiments where T_1 was measured, one group of mice received GdDOTA (30 mM) at a dose of 24 μ mol Gd kg⁻¹ BW (high dose). A lower dose (8 μ mol Gd kg⁻¹ BW, 10 mM) of GdDOTA was also used in the DCE experiments for the sake of comparison.

4.4. MRI

MRI experiments were carried out in a horizontal 9.4 T Bruker Biospec MR system (Bruker Biospin, Wissembourg, France) equipped with gradients capable of switching 950 mTm⁻¹ in 50 μ s. A 12-element linear birdcage coil (Bruker Biospin) with inner diameter 35 mm and length 60 mm was used to achieve uniform excitation and reception.

A custom-built holder was used to fix the animals in the supine position into the birdcage coil. The mice were anesthetized with isoflurane (1.5–2.5%) in an O₂–N₂O 1:1 mixture applied with a face mask allowing free breathing. Respiration was monitored using a balloon taped to the thorax and connected to a pressure transducer (SA Instruments, Inc., Stony Brook, NY, USA). The mice body temperature was monitored with a rectal thermo-sensor and kept at 37 \pm 0.5°C throughout the experiment, using a plastic tube with circulating warm water positioned around their bodies.

4.4.1. DCE experiments

Regional contrast agent uptake was assessed using dynamic contrast enhanced (DCE) MRI. DCE experiments were carried out using a series of 100 inversion-recovery TrueFISP coronal images (1.5 mm thick) of mouse kidneys with an inversion delay of 1.5 s. This inversion time value corresponds to the 'nulling point' for the medulla kidney (T_1 renal medulla > T_1 renal cortex). After adiabatic inversion one image was acquired with the following

parameters: TR/TE = 2/1 ms, at 250 kHz readout bandwidth, 0.95 ms hermite 60° excitation pulse, field-of-view (FOV) = 50×23 mm, matrix = 128×96 . The acquisition time for this image was 291.2 ms. Temporal resolution (i.e. time period between the start of two successive images) was 20 s before CA injection and 6 s thereafter. The overall experimental duration was 12 min.

4.4.2. In vivo T_1 time course measurements

 T_1 measurements were performed using a series of continuous inversion recovery TrueFISP (24) images with the following parameters: TE = 1 ms, TR = 2 ms, flip angle $= 60^{\circ}$, number of T_1 blocks = 80, range of inversion time (TI) = 63.6-5158.9 ms, TI increment (i.e. acquisition time for one frame) = 145.58 ms, number of frames = 36. Bolus injection of the contrast agents, flushed with $\sim 200 \,\mu$ I of saline, was carried out immediately after the sixth IR block. A delay was introduced between the start of two successive blocks to allow for longitudinal relaxation before the next inversion. The temporal resolution (i.e. time period between the start of two successive blocks, or TR_{block}) was 20 s before CA injection and 8 s thereafter; FOV = 50 mm \times 23 mm, matrix = 64×48 , 1 coronal slice, slice thickness = 1.5 mm. The overall experimental duration was 12 min.

4.5. MRI data processing

4.5.1. *T*₁ mapping

Image analysis and processing were performed with the public domain software ImageJ (NIH, http://rsb.info.nih.gov/ij) and MATLAB (Mathworks Inc., Natick, MA, USA). T_1 maps were performed for each time point on a pixel-by-pixel basis from each image using the following model function (24):

$$S(t) = S_{\text{stst}}[1 - INV \cdot \exp(-t/T_1^*)]$$
⁽²⁾

where *S*(*t*) is the signal time course (following an inversion pulse) and *S*_{stst} denotes the steady state signal for large inversion times *t*. *INV*, the inversion factor, is also dependent on relaxation times and is related to the relation between the initial inverted magnetization and the steady-state signal (24). The apparent spin-lattice relaxation time T_1^* describes the dynamic of the signal recovery to *S*_{stst}. If off-resonance effects may be neglected, the following formula relates the fitting parameters of eqn (1) to the longitudinal relaxation time (24):

$$T_1 = T_1^* \cos(\theta/2) (INV - 1), \tag{3}$$

where $\boldsymbol{\theta}$ is the excitation angle.

Regions of interest (ROIs) corresponding to the kidney cortex and medulla, and vascular system, were first drawn on anatomical images and then copy-pasted in the T_1 maps. The time course of the relaxivity rates ($\Delta R_1 \equiv R_1 - R_{10} = 1/T_1 - 1/T_{10}$) was calculated for these ROIs (T_{10} and T_1 are the spin-lattice relaxation values pre- and post-contrast agent injection, respectively).

4.6. Biodistribution and dynamic scintigraphic studies

A γ camera-computer system (GE 400 GenieAcq, from General Electric, Milwaukee, USA) was used for acquisition and pre-processing. Data processing and display were performed on a personal computer using software developed for the IDL 5.2 computer tool. A well counter (DPC-Gamma C12, LA, USA) with a

Compaq DeskPro compatible computer was used for activity counting in the biodistribution studies.

Gamma images were obtained and biological distribution of the $^{153}Sm_3L$ complex was determined using 200 g Wistar rats. All animal studies were carried out in compliance with procedures approved by the appropriate institutional review committees. Conscious rats were allowed free access to food and water. Four animals were anaesthetized with ketamine (50 mg ml $^{-1}$)-chloropromazine (2.5%) (10:3) and injected in the femoral vein with \sim 200 μ Ci of Sm *_3L . The animals were then positioned in dorsal decubitus over the detector. Image acquisition was initiated immediately before radiotracer injection. Sequences of 120 images (of 5 s each), were acquired to 64 \times 64 matrices. Images were subsequently processed using an IDL based program (Interactive Data Language, Research Systems, Boulder, CO, USA).

In order to analyze the transport of the radiotracer over time, four regions of interest (ROI) were drawn on the image files, corresponding to the thorax, liver, left kidney and bladder. The time–activity curves were obtained from these regions. Animals were sacrificed 15 min after injection and the majors organs removed were weighted and counted in a γ well-counter. Similar biodistribution studies with a group of four rats sacrificed 24 h after intravenous injection of ¹⁵³Sm₃L were also performed.

Acknowledgements

This work was financially supported by the Centre National pour la Recherche Scientifique (CNRS, France), the Swiss National Science Foundation, the Swiss State Secretariat for Education and Research (SER), the Foundation of Science and Technology (FCT), Portugal (project POCTI/QUI/47005/2002) and FEDER. It was carried out in the frame of the EC COST Action D38 and the European-founded EMIL programme (LSCH-2004-503569). P.L.S. gratefully acknowledges Le Studium (Agency for research and international hosting associate researchers in 'Region Centre'), Orleans, France for financial support. The authors wish to thank Dr Maria dos Anjos Neves, at the ITN (Instituto Tecnológico e Nuclear), Lisbon, for providing the 153-Samarium chloride (¹⁵³SmCl₃).

REFERENCES

- Pautler RG. Mouse MRI: Concepts and Applications in Physiology. Physiology 2004; 19: 168–175.
- Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999; 99: 2293–2352.
- Merbach AE, Tóth É (eds). The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Wiley: Chichester, 2001.
- 4. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev. 2006; 35: 512.
- Tóth E, Helm L, Merbach AE. Relaxivity of gadolinium(III) complexes: theory and mechanism. In The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging, Merbach AE, Tóth É (eds). Wiley: Chichester, 2001; 45–120.

- Livramento JB, Tóth E, Sour A, Borel A, Merbach AE, Ruloff R. High relaxivity confined to a small molecular space: a metallostarbased, potential MRI contrast agent. Angew. Chem. Int. Edn 2005; 44: 1504–1508.
- Livramento JB, Sour A, Borel A, Merbach AE, Tóth E. Six Gd³⁺ ions densely packed in a starburst-shaped heterometallic compound. Chem. Eur. J. 2006; 12: 989–1003.
- Livramento JB, Weidensteiner C, Prata MIM, Allegrini PR, Geraldes CFGC, Helm L, Kneuer R, Merbach AE, Santos AC, Schmidt P, Tóth É. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity. Contrast Media Mol. Imag. 2006; 1: 30–40.
- Livramento JB, Helm L, Sour A, O'Neil C, Merbach AE, Tóth E. A benzene-core trinuclear Gd^{III} complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field. Dalton Trans. 2008; 1195.
- Brücher E, Sherry AD. Stability and toxicity of contrast agents. In The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging, Tóth E, Merbach AE (eds). Wiley: Chichester, 2001; 243.
- Costa J, Tóth É, Helm L, Merbach AE. Dinuclear, bishydrated Gd^{III} polyaminocarboxylates with a rigid xylene core display remarkable proton relaxivities. Inorg. Chem. 2005; 44: 4747–4755.
- Paul-Roth C, Raymond KN. Amide functional group contribution to the stability of gadolinium(III) complexes: DTPA derivatives. Inorg. Chem. 1995; 34: 1408–1412.
- Tweedle MF, Eaton SM, Eckelman WC, Gaughan GT, Hagan JJ, Wedeking PW, Yost FJ. Comparative chemical structure and pharmacokinetics of mri contrast agents. Invest. Radiol. 1988; 23(suppl. 1): S236–S239.
- Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest. Radiol. 1993; 28(suppl. 1): S28–S43.
- Baumann D, Rudin M. Quantitative assessment of rat kidney function by measuring the clearance of the contrast agent Gd(DOTA) using dynamic MRI. Magn. Res. Imag. 2000; 18: 587–595.
- 16. Pickup S, Wood AKW, Kundel HL. Gadodiamode T_1 relaxivity in the brain tissue in vivo is lower than in saline. Magn. Reson. Med. 2005; 53: 35–40.
- 17. Raghunand N, Howison C, Sherry AD, Zhang S, Gillies RJ. Renal and systemic pH-imaging by contrast-enhanced MRI. Magn. Reson. Med. 2003; 49: 249–257.
- Shuter B, Tofts PS, Wang SC, Pope JM. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat. Magn. Reson. Imag. 1996; 14: 243–253.
- Pedersen M, Morkenborg J, Jensen FT, Stodkilde-Jorgensen H, Djurhuus JC, Frokieer J. In vivo measurements of relaxivities in the rat kidney cortex. Magn. Reson. Imag. 2000; 12: 289–296.
- 20. Gillis A, Gray M, Burstein D. Relaxivity and diffusion of gadolinium agents in cartilage. Magn. Reson. Med. 2002; 48: 1068–1071.
- Aime S, Botta M, Bruce JI, Mainero V, Parker D, Terreno E. Modulation of the water exchange rates in [Gd-DO3A] complex by formation of ternary complexes with carboxylate ligands. Chem. Commun. 2001; 115–116.
- Prata MIM, Santos AC, Neves M, Geraldes CFGC, Lima JJP. ¹⁵³Sm³⁺ and ¹¹¹ln³⁺ DTPA derivatives with high hepatic specificity: in vivo and in vitro studies. J. Inorg. Biochem. 2002; 91: 312–319.
- Alves FC, Donato P, Sherry AD, Zaheer A, Zhang S, Lubag AJM, Merritt ME, Lenkinski RE, Frangioni JV, Neves M, Prata MI, Santos AC, de Lima JJ, Geraldes CF. Silencing of phosphonategadolinium magnetic resonance imaging contrast by hydroxyapatite binding. Invest. Radiol. 2003; 38(12): 750–760.
- Schmitt P, Griswold MA, Jakob PM, Kotas M, Gulani V, Flentje M, Haase A. Inversion recovery TrueFISP: quantification of T₁, T₂, and spin density. Magn. Reson. Med. 2004; 51: 661–667. [Erratum in: Magn. Reson. Med. 2004; 52: 698].